Journal article
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Blood advances, Vol.10(5), pp.1591-1602
03/10/2026
DOI: 10.1182/bloodadvances.2025018079
PMCID: PMC12955621
PMID: 41337699
Abstract
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel endpoints in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months (POD24), clinical trial design, and redefining cure in FL.
Details
- Title: Subtitle
- Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
- Creators
- Reid W Merryman - Dana-Farber Cancer InstituteSarah C Rutherford - Weill Cornell MedicineStephen M Ansell - Mayo ClinicPhilippe Armand - Dana-Farber Cancer InstituteJohn P Leonard - Cornell UniversityLoretta Nastoupil - Southwest Women's OncologySonali M Smith - University of ChicagoJohn M Timmerman - Ronald Reagan UCLA Medical CenterAndrew D Zelenetz - Memorial Sloan Kettering Cancer CenterMeghan Gutierrez - Lymphoma Research FoundationWendy Béguelin - Weill Cornell MedicineCarla Casulo - University of Rochester Medical CenterJames R Cerhan - Mayo ClinicMichael R Green - The University of Texas MD Anderson Cancer CenterBrad S Kahl - Washington University in St. LouisRobert Kridel - Princess Margaret Cancer CentreBrian K Link - University of Iowa, Iowa City, Iowa, United StatesMatthew J Maurer - Mayo ClinicBertrand Nadel - Centre d’Immunologie de Marseille-LuminyAndrea Radtke - Leidos (United States)Efrat Luttwak - Memorial Sloan Kettering Cancer CenterGilles A Salles - Memorial Sloan Kettering Cancer CenterLaurie H Sehn - BC Cancer FoundationLaura Pasqualucci - Columbia UniversityAnn S LaCasce - Dana-Farber Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Blood advances, Vol.10(5), pp.1591-1602
- DOI
- 10.1182/bloodadvances.2025018079
- PMID
- 41337699
- PMCID
- PMC12955621
- NLM abbreviation
- Blood Adv
- ISSN
- 2473-9537
- eISSN
- 2473-9537
- Publisher
- ELSEVIER; AMSTERDAM
- Grant note
- Leukemia and Lymphoma Society Scholar awardIntramural Research Program of the National Institutes of HealthLymphoma Research Foundation as part of the Jaime Peykoff Follicular Lymphoma Initiative
M. Green is supported by a Leukemia and Lymphoma Society Scholar award. A.J.R. was supported by the Intramural Research Program of the National Institutes of Health, including National Institute of Allergy and Infectious Diseases and National Cancer Institute, at the time of this workshop. The workshop was supported by grants from the Lymphoma Research Foundation as part of the Jaime Peykoff Follicular Lymphoma Initiative.
- Language
- English
- Electronic publication date
- 12/03/2025
- Date published
- 03/10/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9985090624602771
Metrics
9 Record Views